Page last updated: 2024-09-05

glaucocalyxin b and Idiopathic Parkinson Disease

glaucocalyxin b has been researched along with Idiopathic Parkinson Disease in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Li, J; Liu, Y; Shang, X; Xu, W; Yang, L; Zheng, D	1

Other Studies

1 other study(ies) available for glaucocalyxin b and Idiopathic Parkinson Disease

Article	Year
Glaucocalyxin B Alleviates Lipopolysaccharide-Induced Parkinson's Disease by Inhibiting TLR/NF-κB and Activating Nrf2/HO-1 Pathway. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2017, Volume: 44, Issue:6 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Diterpenes, Kaurane; Heme Oxygenase-1; Inflammation; Lipopolysaccharides; Mice; NF-E2-Related Factor 2; NF-kappa B; Parkinson Disease; Rats, Sprague-Dawley; Signal Transduction; Toll-Like Receptors	2017

Article

Year

Glaucocalyxin B Alleviates Lipopolysaccharide-Induced Parkinson's Disease by Inhibiting TLR/NF-κB and Activating Nrf2/HO-1 Pathway.

Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2017, Volume: 44, Issue:6

Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Diterpenes, Kaurane; Heme Oxygenase-1; Inflammation; Lipopolysaccharides; Mice; NF-E2-Related Factor 2; NF-kappa B; Parkinson Disease; Rats, Sprague-Dawley; Signal Transduction; Toll-Like Receptors

2017